Prometic Life Sciences Inc., of Laval, Quebec, presented data at the American Thoracic Society International Conference in Washington, including results from a phase II study showing that lung function in 25 idiopathic pulmonary fibrosis patients receiving either PBI-4050 alone or PBI-4050 in combination with Ofev (nintedanib, Boehringer Ingelheim GmbH) remained stable as measured by the difference between the forced vital capacity (FVC) at baseline and following 12 weeks of treatment.